Patients on Osteoporosis’ Medication May Develop Eye Disorder, Say Researchers

.

Patients on Osteoporosis’ Medication May Develop Eye Disorder, Say Researchers

For the very first time, a study has showed that patients on osteoporosis’ medication are at a higher risk of being affected with inflammatory eye disease. The study was conducted by the researchers of Child and Family Research Institute located in Vancouver.

During the study, the researchers examined the effect of osteoporosis’ medication, oral bisphosphonates over eye conditions uveitis and scleritis. During the study, it was found that the patients on bisphosphonates were at higher risk of developing the eye disorders.

The findings of the study have been published in the journal Canadian Medical Association. For the study, the researchers analyzed the data of 934,147 patients. The majority of the patients were not taking the bisphosphonates.

The researchers informed that patients who had been taking bisphosphonates for the very first time were more likely to be affected with uveitis and scleritis. The author of the study noted, “Our study highlights the need for clinicians to inform their patients about the signs and symptoms of scleritis and uveitis, so that prompt treatment may be sought and further complications averted”.

The findings have stirred unrest among the health experts, as it is for the very first time when a study has showed that the osteoporosis’ medication can have adverse outcomes on the health of the patients.


Latest News

Rise in Russian Arms Sales In spite of a Drop Globally
PetSmart Sells itself with an $8.3Billion Deal
Falling Oil Prices Result in a Drop in Stocks
Shares of Amaya Fall Due to Probe Conducted by Securities Regulators
Americans Consumers Display Confidence In the Market with Gain in Sales
It’s Time to Hurry Up to Enrol in the First Phase of Affordable Care Act Health
After Merger with Alliance Boots,	Walgreen CEO will Retire
Falling Fuel Prices Lift Airline Profits But No Respite in Fares Expected
Citigroup to Pay Likely $2.7B as Legal Charge
Michael Jeffries Retires as the CEO of Abercrombie & Fitch
Deutsche Bank in Trouble Again in the U.S. for Alleged Tax Scheme
Popular Demand Brings French Toast Crunch Back on the Shelves